JP7159148B2 - Ｔｇｆベータスーパーファミリーホモ多量体およびその使用 - Google Patents
Ｔｇｆベータスーパーファミリーホモ多量体およびその使用 Download PDFInfo
- Publication number
- JP7159148B2 JP7159148B2 JP2019500446A JP2019500446A JP7159148B2 JP 7159148 B2 JP7159148 B2 JP 7159148B2 JP 2019500446 A JP2019500446 A JP 2019500446A JP 2019500446 A JP2019500446 A JP 2019500446A JP 7159148 B2 JP7159148 B2 JP 7159148B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acids
- heteromultimer
- heteromultimers
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004887 Transforming Growth Factor beta Human genes 0.000 title description 306
- 108090001012 Transforming Growth Factor beta Proteins 0.000 title description 306
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title description 306
- 150000001413 amino acids Chemical class 0.000 claims description 650
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 608
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 608
- 229920001184 polypeptide Polymers 0.000 claims description 607
- 108010036395 Endoglin Proteins 0.000 claims description 112
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims description 3
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 3
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 claims description 3
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims 19
- 102000037865 fusion proteins Human genes 0.000 claims 19
- 239000000833 heterodimer Substances 0.000 claims 18
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 102100037241 Endoglin Human genes 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 639
- 229940024606 amino acid Drugs 0.000 description 639
- 239000003446 ligand Substances 0.000 description 377
- 108010051765 Type I Bone Morphogenetic Protein Receptors Proteins 0.000 description 250
- 238000003556 assay Methods 0.000 description 218
- 230000027455 binding Effects 0.000 description 217
- 239000012634 fragment Substances 0.000 description 151
- 102100034135 Activin receptor type-1C Human genes 0.000 description 149
- 101710173005 Activin receptor type-1C Proteins 0.000 description 149
- 230000011664 signaling Effects 0.000 description 148
- 230000005764 inhibitory process Effects 0.000 description 145
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 description 140
- 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 140
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 134
- 102000019044 Type I Bone Morphogenetic Protein Receptors Human genes 0.000 description 132
- 102100034134 Activin receptor type-1B Human genes 0.000 description 130
- 101710173011 Activin receptor type-1B Proteins 0.000 description 130
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 128
- 102100034111 Activin receptor type-1 Human genes 0.000 description 124
- 102100025440 BMP-binding endothelial regulator protein Human genes 0.000 description 123
- 101000934632 Homo sapiens BMP-binding endothelial regulator protein Proteins 0.000 description 123
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 119
- 102000012085 Endoglin Human genes 0.000 description 111
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 109
- 102100024300 Cryptic protein Human genes 0.000 description 104
- 101710185307 Cryptic protein Proteins 0.000 description 104
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 102
- 108010079292 betaglycan Proteins 0.000 description 102
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 description 95
- 102100024292 Cryptic family protein 1B Human genes 0.000 description 93
- 101710201184 Cryptic family protein 1B Proteins 0.000 description 93
- 102100037150 BMP and activin membrane-bound inhibitor homolog Human genes 0.000 description 81
- 101000740070 Homo sapiens BMP and activin membrane-bound inhibitor homolog Proteins 0.000 description 81
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 description 81
- 210000004027 cell Anatomy 0.000 description 75
- 238000000338 in vitro Methods 0.000 description 72
- 230000000875 corresponding effect Effects 0.000 description 43
- 102000005962 receptors Human genes 0.000 description 20
- 108020003175 receptors Proteins 0.000 description 20
- 108010059616 Activins Proteins 0.000 description 15
- 102100026818 Inhibin beta E chain Human genes 0.000 description 15
- 239000000488 activin Substances 0.000 description 15
- 239000000539 dimer Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- -1 Cryptic Proteins 0.000 description 5
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 5
- 101000958045 Homo sapiens Muscle, skeletal receptor tyrosine-protein kinase Proteins 0.000 description 5
- 102100038168 Muscle, skeletal receptor tyrosine-protein kinase Human genes 0.000 description 5
- 108010056852 Myostatin Proteins 0.000 description 5
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 4
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 4
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 4
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 4
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 4
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 4
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 4
- 102100022816 Hemojuvelin Human genes 0.000 description 4
- 108050008605 Hemojuvelin Proteins 0.000 description 4
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 4
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 4
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 4
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 4
- 101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 description 4
- 102000043168 TGF-beta family Human genes 0.000 description 3
- 108091085018 TGF-beta family Proteins 0.000 description 3
- 102100026376 Artemin Human genes 0.000 description 2
- 101710205806 Artemin Proteins 0.000 description 2
- 102100028727 Bone morphogenetic protein 15 Human genes 0.000 description 2
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 2
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 2
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 2
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 2
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 description 2
- 101000695360 Homo sapiens Bone morphogenetic protein 15 Proteins 0.000 description 2
- 101000762375 Homo sapiens Bone morphogenetic protein 3 Proteins 0.000 description 2
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 description 2
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 description 2
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 2
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 2
- 101001023988 Homo sapiens Growth/differentiation factor 5 Proteins 0.000 description 2
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 description 2
- 101000692878 Homo sapiens Regulator of MON1-CCZ1 complex Proteins 0.000 description 2
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 2
- 102100021584 Neurturin Human genes 0.000 description 2
- 108010015406 Neurturin Proteins 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 2
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 108010023079 activin B Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102100021886 Activin receptor type-2A Human genes 0.000 description 1
- 102100027647 Activin receptor type-2B Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 102000010571 Type II Bone Morphogenetic Protein Receptors Human genes 0.000 description 1
- 108010063130 Type II Bone Morphogenetic Protein Receptors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010057429 activin receptor type II-A Proteins 0.000 description 1
- 108010057453 activin receptor type II-B Proteins 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000007261 regionalization Effects 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022144508A JP2022172479A (ja) | 2016-07-07 | 2022-09-12 | Ｔｇｆベータスーパーファミリーホモ多量体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359614P | 2016-07-07 | 2016-07-07 | |
| US62/359,614 | 2016-07-07 | ||
| US201662404670P | 2016-10-05 | 2016-10-05 | |
| US62/404,670 | 2016-10-05 | ||
| PCT/US2017/040849 WO2018009624A1 (en) | 2016-07-07 | 2017-07-06 | Tgf-beta superfamily heteromultimers and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022144508A Division JP2022172479A (ja) | 2016-07-07 | 2022-09-12 | Ｔｇｆベータスーパーファミリーホモ多量体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527547A JP2019527547A (ja) | 2019-10-03 |
| JP2019527547A5 JP2019527547A5 (https=) | 2022-09-22 |
| JP7159148B2 true JP7159148B2 (ja) | 2022-10-24 |
Family
ID=60913181
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500446A Active JP7159148B2 (ja) | 2016-07-07 | 2017-07-06 | Ｔｇｆベータスーパーファミリーホモ多量体およびその使用 |
| JP2022144508A Pending JP2022172479A (ja) | 2016-07-07 | 2022-09-12 | Ｔｇｆベータスーパーファミリーホモ多量体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022144508A Pending JP2022172479A (ja) | 2016-07-07 | 2022-09-12 | Ｔｇｆベータスーパーファミリーホモ多量体およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200071382A1 (https=) |
| EP (1) | EP3481860A4 (https=) |
| JP (2) | JP7159148B2 (https=) |
| AU (2) | AU2017293778B2 (https=) |
| CA (1) | CA3029890A1 (https=) |
| WO (1) | WO2018009624A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10358476B2 (en) | 2015-04-06 | 2019-07-23 | Acceleron Pharma Inc. | Single arm type I and type II receptor fusion proteins and uses thereof |
| MA41920B1 (fr) | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| CA3039573A1 (en) | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Alk4:actriib heteromultimers and uses thereof |
| CN110036025B (zh) | 2016-10-05 | 2024-03-22 | 阿塞勒隆制药公司 | 变体ActRIIB蛋白及其用途 |
| US12103959B2 (en) | 2018-05-03 | 2024-10-01 | Acceleron Pharma Inc. | Multispecific binders of TGFBeta-superfamily ligands and uses thereof |
| CA3103427A1 (en) * | 2018-06-15 | 2019-12-19 | Acceleron Pharma Inc. | Bi-and tri-functional fusion proteins and uses thereof |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| JP2024540480A (ja) | 2021-11-17 | 2024-10-31 | ディスク・メディシン・インコーポレイテッド | 腎臓疾患の貧血を処置する方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014055869A1 (en) | 2012-10-05 | 2014-04-10 | Acceleron Pharma, Inc. | Treatment of cancer with alk1 antagonists |
| JP2014510084A (ja) | 2011-03-17 | 2014-04-24 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | 二重特異性および単一特異性の非対称な抗体ならびにそれらの作製方法 |
| WO2015160940A1 (en) | 2014-04-15 | 2015-10-22 | President And Fellows Of Harvard College | Bi-specific agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6250533B2 (ja) * | 2011-04-20 | 2017-12-20 | アクセレロン ファーマ インコーポレイテッドＡｃｃｅｌｅｒｏｎ Ｐｈａｒｍａ，Ｉｎｃ． | エンドグリンポリペプチドおよびその使用 |
| EP3851118A1 (en) * | 2013-10-25 | 2021-07-21 | Acceleron Pharma Inc. | Endoglin peptides to treat fibrotic diseases |
| WO2015147908A1 (en) * | 2014-03-28 | 2015-10-01 | Acceleron Pharma, Inc. | Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer |
-
2017
- 2017-07-06 CA CA3029890A patent/CA3029890A1/en active Pending
- 2017-07-06 AU AU2017293778A patent/AU2017293778B2/en not_active Ceased
- 2017-07-06 US US16/315,338 patent/US20200071382A1/en not_active Abandoned
- 2017-07-06 WO PCT/US2017/040849 patent/WO2018009624A1/en not_active Ceased
- 2017-07-06 JP JP2019500446A patent/JP7159148B2/ja active Active
- 2017-07-06 EP EP17824864.7A patent/EP3481860A4/en not_active Withdrawn
-
2022
- 2022-03-08 AU AU2022201603A patent/AU2022201603A1/en not_active Abandoned
- 2022-09-12 JP JP2022144508A patent/JP2022172479A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014510084A (ja) | 2011-03-17 | 2014-04-24 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | 二重特異性および単一特異性の非対称な抗体ならびにそれらの作製方法 |
| WO2014055869A1 (en) | 2012-10-05 | 2014-04-10 | Acceleron Pharma, Inc. | Treatment of cancer with alk1 antagonists |
| WO2015160940A1 (en) | 2014-04-15 | 2015-10-22 | President And Fellows Of Harvard College | Bi-specific agents |
Non-Patent Citations (2)
| Title |
|---|
| J. Biochem. Mol. Biol.，2011年，vol.286, no.34, p.30034-30046 |
| Molecular Biology of theCell，2015年，vol.26, p.3117-3127 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3481860A1 (en) | 2019-05-15 |
| JP2019527547A (ja) | 2019-10-03 |
| JP2022172479A (ja) | 2022-11-16 |
| AU2017293778B2 (en) | 2022-03-24 |
| US20200071382A1 (en) | 2020-03-05 |
| WO2018009624A1 (en) | 2018-01-11 |
| AU2022201603A1 (en) | 2022-03-31 |
| CA3029890A1 (en) | 2018-01-11 |
| AU2017293778A1 (en) | 2019-01-24 |
| EP3481860A4 (en) | 2020-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7617962B2 (ja) | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 | |
| JP7203807B2 (ja) | シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用 | |
| JP7037363B2 (ja) | Ｔｇｆベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体およびその使用 | |
| JP7159148B2 (ja) | Ｔｇｆベータスーパーファミリーホモ多量体およびその使用 | |
| JP7504947B2 (ja) | Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用 | |
| JP2019527547A5 (https=) | ||
| JP2023528709A (ja) | バリアントａｃｔｒｉｉｂタンパク質およびその使用 | |
| HK40078293A (en) | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof | |
| HK40057061A (en) | Single-arm type i and type ii receptor fusion proteins and uses thereof | |
| EP3735418A1 (en) | Single-arm co-receptor fusion proteins and uses thereof | |
| HK1248733B (en) | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof | |
| HK1252958B (zh) | 单臂i型和ii型受体融合蛋白和其用途 | |
| HK1248732B (en) | Single-arm type i and type ii receptor fusion proteins and uses thereof | |
| HK40011178A (zh) | 变体actriib蛋白及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200703 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200703 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210407 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210521 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210708 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220315 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220614 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220812 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20220912 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220926 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221012 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7159148 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |